Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712689 | 0.94 | KDM4E (0.34) | MAPK14BCHEACHEALDH1A1POLB | |
| SCHEMBL13712688 | 0.88 | MAPK14 (0.33) | MAPK14BCHEACHEALDH1A1POLB | |
| SCHEMBL12134734 | 0.83 | ALDH1A1 (0.40) | MAPK14BCHEACHEALDH1A1POLB | |
| SCHEMBL12132912 | 0.83 | ALDH1A1 (0.40) | MAPK14BCHEACHEALDH1A1KDM4E | |
| SCHEMBL13712727 | 0.79 | MAPK14 (0.33) | MAPK14BCHEACHEALDH1A1POLB | |
| SCHEMBL12134963 | 0.79 | KDM4E (0.43) | ALDH1A1POLBKDM4ENPC1MAPT | |
| SCHEMBL12134965 | 0.74 | PIK3CG (0.33) | — | |
| SCHEMBL14425596 | 0.71 | NQO2 (0.42) | ALDH1A1POLBKDM4ENPC1MAPT | |
| SCHEMBL12134729 | 0.71 | ALDH1A1 (0.37) | ALDH1A1POLBKDM4ENPC1MAPT | |
| SCHEMBL22793039 | 0.71 | NPSR1 (0.34) | MAPK14BCHEACHEALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705014-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090062327-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-7396832-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | MAPK14 359/4885BCHE 2315/4885ACHE 2354/4885 |
| US-20090062327-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | MAPK14 374/4885BCHE 3622/4885ACHE 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.